July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Long-Term Growth and Systemic Outcomes in Laser and Bevacizumab-Treated Infants with Retinopathy of Prematurity
Author Affiliations & Notes
  • Margaret Littlejohn
    School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Lingkun Kong
    Ophthalmology, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Ann Demney
    Pediatrics, Texas Children's Hospital, Houston, Texas, United States
  • Robert G. Voigt
    Pediatrics, Texas Children's Hospital, Houston, Texas, United States
  • Sonia A. Monteiro
    Pediatrics, Texas Children's Hospital, Houston, Texas, United States
  • Footnotes
    Commercial Relationships   Margaret Littlejohn, None; Lingkun Kong, None; Ann Demney, None; Robert Voigt, None; Sonia Monteiro, None
  • Footnotes
    Support  Knights Templar Eye Foundation
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3764. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Margaret Littlejohn, Lingkun Kong, Ann Demney, Robert G. Voigt, Sonia A. Monteiro; Long-Term Growth and Systemic Outcomes in Laser and Bevacizumab-Treated Infants with Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3764.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Recent usage of intravitreal bevacizumab (IVB) to treat retinopathy of prematurity (ROP) has led to questions regarding the systemic absorption of bevacizumab and its potential long-term side effects. We performed a prospective, observational clinical study to test the hypothesis that IVB-treated infants have the similar long-term growth and systemic outcomes compared to laser-treated infants.

Methods : Total of 67 infants were who were treated with IVB injection (N=47) or laser (N=20) from 2010 to 2014 were enrolled. The neurodevelopmental outcome measurements include body weight (BW), height and head circumference (HC) at age 1 and 3; neurodevelopmental quotient (DQ) at age 1 and 3. Systemic multi-organ functional outcomes include: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and gamma-glutamyl transferase (GGT), conjugated and unconjugated bilirubin, and albumin levels for liver; blood urea nitrogen (BUN) and creatinine levels for kidney at 2 months post-teatment and 1 and 3 years of age. Two-tailed Student’s t-tests were used to compare the group means of the IVB-treated and laser-treated groups.

Results : There was global developmental delay in both groups. Patients in both groups showed progress over time, but the changes were not significant, p=0.1 to 0.7. There were no significant differences in neurodevelopmental sub-domains (gross motor, visual-motor problem solving, and language DQ), body weight, height and HC between the two groups at age 1 and 3, p=0.3. Infants treated with IVB had lower AST levels (p=.002) at 2 months post treatment as well as lower albumin levels (p=.034) at 4 weeks post treatment. Other hepatic lab values showed non-significant differences. IVB treated infants showed lower creatinine levels (p=.013) at 2 months post treatment. Other renal lab values showed non-significant differences in groups. IVB treated infants demonstrated significantly lower blood glucose (p=.041) at 2 years of age. Other blood glucose readings showed non-significant differences between groups. No significant differences between IVB and laser treated infants were demonstrated in hemoglobin, hematocrit, or platelet counts.

Conclusions : Our results indicate that there were differences in liver, kidney and blood glucose lab tests between IVB and laser treated infants. The clinical significance among these changes needs to be investigated.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×